Western blot analysis of extracts from various cell lines using Pim-1 (C93F2) Rabbit mAb.
Western blot analysis of extracts from K-562, Raji and KARPAS-620 cell lines using Pim-2 (D1D2) Rabbit mAb.
Western blot analysis of extracts from various cell lines using Pim-3 (D17C9) Rabbit mAb.
Flow cytometric analysis of COS cells, untreated (blue) or TPA/Calyculin A treated (green), using Phospho-Bad (Ser112) (40A9) Rabbit mAb.
Western blot analysis of extracts from various cell lines using Bad (D24A9) Rabbit mAb.
After the primary antibody is bound to the target protein, a complex with HRP-linked secondary antibody is formed. The LumiGLO® is added and emits light during enzyme catalyzed decomposition.
Western blot analysis of recombinant Pim-1, -2, and -3 using Pim-1 (C93F2) Rabbit mAb.
Western blot analysis of recombinant Pim-1, Pim-2 and Pim-3 kinases using Pim-2 (D1D2) Rabbit mAb.
Western blot analysis of recombinant Pim-1, 2, and 3 using Pim-3 (D17C9) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, untreated (left) or lambda phosphatase treated (right), using Phospho-Bad (Ser 112) (40A9) Rabbit mAb.
Western blot analysis of extracts from COS-7 cells, untransfected () or transfected with a mouse Pim-3 construct (+), using Pim-3 (D17C9) Rabbit mAb.
Immunohistochemical analysis of paraffin embedded COS cells untreated (left) or TPA-treated (right), showing induced cytoplasmic staining using Phospho-Bad (Ser112) (40A9) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human prostate carcinoma, using Phospho-Bad (Ser 112) (40A9) Rabbit Monoclonal Antibody preincubated with control peptide (left) or Phospho-Bad (Ser 112) Blocking Peptide (IHC Specific) #1026 (right).
Immunohistochemical analysis of paraffin-embedded Non-Hodgkin's lymphoma, using Phospho-Bad (Ser112) (40A9) Rabbit mAb.
Western blot analysis of extracts from COS cells, untreated or TPA-treated, using Phospho-Bad (Ser112) (40A9) Rabbit mAb (upper) or Bad Antibody #9292 (lower).
|Pim-1 (C93F2) Rabbit mAb 3247||20 µl||
||H M||34||Rabbit IgG|
|Pim-2 (D1D2) Rabbit mAb 4730||20 µl||
||H||40, 38, 34||Rabbit|
|Pim-3 (D17C9) Rabbit mAb 4165||20 µl||
||H M R||35||Rabbit IgG|
|Phospho-Bad (Ser112) (40A9) Rabbit mAb 5284||20 µl||
||H M R Mk||23||Rabbit IgG|
|Bad (D24A9) Rabbit mAb 9239||20 µl||
||H M R Mk||23||Rabbit IgG|
|Anti-rabbit IgG, HRP-linked Antibody 7074||100 µl||
The Pim Kinase Antibody Sampler Kit provides an economical means to detect all three Pim kinases along with Bad and Phospho-Bad (Ser112). The kit contains enough primary and secondary antibody to perform two western blot experiments.
The Pim-1 (C93F2) Rabbit mAb, Pim-2 (D1D2) Rabbit mAb, and Pim-3 (D17C9) Rabbit mAb detect endogenous levels of the respective proteins. The Pim antibodies do not crossreact with other Pim family members. Phospho-Bad (Ser112) (40A9) Rabbit mAb detects endogenous levels of Bad only when phosphorylated at Ser112. It does not detect Bad phosphorylated at other sites, nor does it detect related family members. Bad (D24A9) Rabbit mAb detects endogenous levels of total Bad protein.
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val160 of human Pim-1, Cys266 of human Pim-2, Ser275 of human Pim-3, Ser112 of mouse Bad, and Pro102 of human Bad, respectively.
Pim proteins (Pim-1, Pim-2 and Pim-3) are oncogene-encoded serine/threonine kinases (1). Pim-1, a serine/threonine kinase highly expressed in hematopoietic cells, plays a critical role in the transduction of mitogenic signals and is rapidly induced by a variety of growth factors and cytokines (1-4). Pim-1 cooperates with c-Myc in lymphoid cell transformation and protects cells from growth factor withdrawal and genotoxic stress-induced apoptosis (5,6). Pim-1 also enhances the transcriptional activity of c-Myb through direct phosphorylation within the c-Myb DNA binding domain as well as phosphorylation of the transcriptional coactivator p100 (7,8). Hypermutations of the Pim-1 gene are found in B-cell diffuse large cell lymphomas (9). Phosphorylation of Pim-1 at Tyr218 by Etk occurs following IL-6 stimulation and correlates with an increase in Pim-1 activity (10). Various Pim substrates have been identified; Bad is phosphorylated by both Pim-1 and Pim-2 at Ser112 and this phosphorylation reverses Bad-induced cell apoptosis (11,12).
The corresponding pim-1 gene encodes a pair of proteins through use of different translation initiation sites. Both larger 44 kDa (Pim-1L) and smaller 33 kDa (Pim-1S) proteins are active kinases, but differ in stability (13).
Explore pathways + proteins related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.